chevron_left
ASH 2022
1. Maintenance Cessation in MRD Negative Patients | Neha Korde, MD | ASH 2022 Video
bookmark_border
2. Individualized Prediction Model in Myeloma & Genome Sequencing | Francesco Maura, MD | ASH 2022 Video
bookmark_border
3. MODAKAFUSP ALFA (TAK-573) | Dan Vogl, MD, MSCE | ASH 2022 Video
bookmark_border
4. Opioid Use in Managing Pain in Myeloma | Karen Sweiss, PharmD | ASH 2022 Video
bookmark_border
5. Frailty and Multiple Myeloma | Hira Mian, MD, MSc | ASH 2022 Video
bookmark_border
6. MajesTEC-2 Trial | Emma Searle, MBChB MA MRCP FRCPath PhD | ASH 2022 Video
bookmark_border
7. Barriers to Participation in Hematology Trials | Shakira Grant, MBBS & Jiona Mills | ASH 2022 Video
bookmark_borderadjust
8. Talquetamab | Ajai Chari, MD | ASH 2022 Video
bookmark_border
9. OPTIMUM MUK Nine Trial | Martin Kaiser, MD | ASH 2022 Video
bookmark_border
10. How to Better Diagnose Patients With High-Risk Myeloma | Martin Kaiser, MD | ASH 2022 Video
bookmark_border
11. Waitlists for CAR-T | Samer Al'Hadidi, MD | ASH 2022 Video
bookmark_border
12. The Need for New Clinical Trial Strategies | Hearn J. Cho, MD | ASH 2022 Video
bookmark_border
13. Advancements in Immunotherapy Agents | Hearn J. Cho, MD | ASH 2022 Video
bookmark_border
14. Nutrivention Trials | Urvi Shah, MD | ASH 2022 Video
bookmark_border
15. Building a Dietary Evidence Symposium | Urvi Shah, MD | ASH 2022 Video
bookmark_border
16. T Cell Redirection Therapy | Tarek Mouhieddine, MD | ASH 2022 Video
bookmark_border
17. Bispecifics | Urvi Shah, MD | ASH 2022 Video
bookmark_border
18. CAR-T Therapy | Santiago Thibaud, MD | ASH 2022 Video
bookmark_border
19. CAR-T BMS-986354 | Luciano Costa, MD, PhD | ASH 2022 Video
bookmark_border
20. Maintenance Cessation in MRD Negative Patients | Neha Korde, MD | ASH 2022 Video
bookmark_border
21. Effect of a Covid Infection in Patients Prior to Transplant | Meera Mohan, MD, MS, FACP | ASH 2022 Video
bookmark_border
22. New Developments at ASH | Rafat Abonour, MD | ASH 2022 Video
bookmark_border
23. Quad Therapies and Side Effects | Nathan Sweeney, PhD | ASH 2022 Video
bookmark_border
24. Patient Top Concerns At and Since Diagnosis | Nathan Sweeney, PhD | ASH 2022 Video
bookmark_border
25. Bispecific T Cell Engagers | Noopur Raje, MD | ASH 2022 Video
bookmark_border
26. Revlimid Refractory Patients in Daratumumab Clinical Trials | Binod Dhakal, MD | ASH 2022 Video
bookmark_border
27. MRD Detection in Blood | Bruno Paiva, PhD | ASH 2022 Video
bookmark_border
28. iStopMM Trial - Covid Vaccine and Impact on Myeloma | Malin Hultcrantz, MD, PhD | ASH 2022 Video
bookmark_border
29. Post BCMA Therapy | Gurbakhash Kaur, MD | ASH 2022 Video
bookmark_border
30. LINKER-MM1 Study in RRMM | Naresh Bumma, MD | ASH 2022 Video
bookmark_border
31. Updates on Teclistamab, Talquetamab, and CARVYKTI | Mark Wildgust, PhD | ASH 2022 Video
bookmark_border
32. Bispecific Antibodies | Joshua Richter, MD | ASH 2022 Video
bookmark_border
33. Prospective Evaluation of the Biology of Aggressive Myeloma Lesions After Induction | ASH 2022 Video
bookmark_border
34. Detecting Myeloma with Single Cell Sequencing | Scott Goldsmith, MD | ASH 2022 Video
bookmark_border
35. What to Look Forward to at ASH | Ola Landgren, MD, PhD | ASH 2022 Video
bookmark_border![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}